These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 19337444)
61. [Efficacy and feasibility evaluation in long term pamidronate treatment of bone metastases]. Senkus-Konefka E; Krasińska L; Pikiel J; Krasińska W; Nowaczyk M; Jassem J Przegl Lek; 2003; 60(7):467-70. PubMed ID: 14750420 [TBL] [Abstract][Full Text] [Related]
62. Home care versus hospital care in patients with multiple myeloma treated with pamidronate. Smith AG; Soutar RL; Schey S; Andrews CD; Baister ER; Bilbrough C; Connelly M; Joyce A; Child JA Int J Palliat Nurs; 2004 Mar; 10(3):144-9. PubMed ID: 15126959 [TBL] [Abstract][Full Text] [Related]
63. Zoledronic acid in cancer patients with bone metastases: results of Phase I and II trials. Berenson JR Semin Oncol; 2001 Apr; 28(2 Suppl 6):25-34. PubMed ID: 11346862 [TBL] [Abstract][Full Text] [Related]
64. [Phase III clinical study of zoledronic acid in the treatment of pain induced by bone metastasis from solid tumor or multiple myeloma]. Dong M; Feng FY; Zhang Y; Xie GR; Wang YJ; Liu JW; Song ST; Zhou QH; Ren J; Jiao SC; Li J; Wang XW; Chen Q; Wang ZH; Xu N; Feng JF Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):215-20. PubMed ID: 18756940 [TBL] [Abstract][Full Text] [Related]
65. Renal safety and efficacy of i.v. bisphosphonates in patients with skeletal metastases treated for up to 10 Years. Guarneri V; Donati S; Nicolini M; Giovannelli S; D'Amico R; Conte PF Oncologist; 2005; 10(10):842-8. PubMed ID: 16314295 [TBL] [Abstract][Full Text] [Related]
66. Patient management, and time and health care resource utilization associated with the use of intravenous bisphosphonates for patients with metastatic bone disease: a Delphi study. Xie F; Hopkins R; Burke N; Tarride JE; Goeree R Hosp Pract (1995); 2012 Apr; 40(2):131-7. PubMed ID: 22615087 [TBL] [Abstract][Full Text] [Related]
67. Bisphosphonate treatment of lytic bone metastases. Lipton A; Berenson JR Drugs Aging; 1999 Apr; 14(4):241-6. PubMed ID: 10319239 [TBL] [Abstract][Full Text] [Related]
68. Bisphosphonates in multiple myeloma. Djulbegovic B; Wheatley K; Ross J; Clark O; Bos G; Goldschmidt H; Cremer F; Alsina M; Glasmacher A Cochrane Database Syst Rev; 2002; (3):CD003188. PubMed ID: 12137679 [TBL] [Abstract][Full Text] [Related]
69. Bisphosphonates in multiple myeloma. Djulbegovic B; Wheatley K; Ross J; Clark O; Bos G; Goldschmidt H; Cremer F; Alsina M; Glasmacher A Cochrane Database Syst Rev; 2001; (4):CD003188. PubMed ID: 11687178 [TBL] [Abstract][Full Text] [Related]
70. Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases. Cremers SC; Papapoulos SE; Gelderblom H; Seynaeve C; den Hartigh J; Vermeij P; van der Rijt CC; van Zuylen L J Bone Miner Res; 2005 Sep; 20(9):1543-7. PubMed ID: 16059626 [TBL] [Abstract][Full Text] [Related]
71. [Pamidronate in the treatment of bone metastases from breast cancer]. Nagykálnai T; Landherr L; Zatkóné GP; Gyuricska A Magy Onkol; 2002; 46(3):225-33. PubMed ID: 12368918 [TBL] [Abstract][Full Text] [Related]
72. Pamidronate for the prevention of skeletal-related events in multiple myeloma. What does the public think it is worth? Dranitsaris G Int J Technol Assess Health Care; 1999; 15(1):108-22. PubMed ID: 10407599 [TBL] [Abstract][Full Text] [Related]
73. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Boonyapakorn T; Schirmer I; Reichart PA; Sturm I; Massenkeil G Oral Oncol; 2008 Sep; 44(9):857-69. PubMed ID: 18282788 [TBL] [Abstract][Full Text] [Related]
74. Recovery of serum calcium concentrations following acute hypocalcemia in patients with osteoporosis on long-term oral therapy with the bisphosphonate pamidronate. Landman JO; Schweitzer DH; Frölich M; Hamdy NA; Papapoulos SE J Clin Endocrinol Metab; 1995 Feb; 80(2):524-8. PubMed ID: 7852514 [TBL] [Abstract][Full Text] [Related]
75. Bisphosphonate therapy in multiple myeloma. Laakso M; Jantunen E Acta Oncol; 1996; 35 Suppl 5():55-6. PubMed ID: 9142966 [TBL] [Abstract][Full Text] [Related]
76. Intravenously administered pamidronate in the treatment of Paget's disease of bone. Tucci JR; Bontha S Endocr Pract; 2001; 7(6):423-9. PubMed ID: 11747277 [TBL] [Abstract][Full Text] [Related]
77. Clinical experience with pamidronate in the treatment of Paget's disease of bone. Gallacher SJ; Boyce BF; Patel U; Jenkins A; Ralston SH; Boyle IT Ann Rheum Dis; 1991 Dec; 50(12):930-3. PubMed ID: 1768163 [TBL] [Abstract][Full Text] [Related]
79. Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate. Pecherstorfer M; Steinhauer EU; Rizzoli R; Wetterwald M; Bergström B Support Care Cancer; 2003 Aug; 11(8):539-47. PubMed ID: 12783289 [TBL] [Abstract][Full Text] [Related]
80. In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Aparicio A; Gardner A; Tu Y; Savage A; Berenson J; Lichtenstein A Leukemia; 1998 Feb; 12(2):220-9. PubMed ID: 9519785 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]